MarketPeel
Insider Trading Intelligence
DK

David Kirn

FDMT
CHIEF EXECUTIVE OFFICER · 4D MOLECULAR THERAPEUTICS, INC. · CIK 0001834021
FILING MIX · LIFETIME29%/71%
BUYS
10
SELLS
24
TOTAL VALUE
$9.86M
COMPANIES
1
ACTIVE SINCE
Mar 2021
HOLDINGS NOW
942,485
AVG SELL PX
$19.63
TRADE KIND
SHOWING 34 / 34
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
18 backtested trades · 8 horizons · 1 pending
Forward-return performance of every backtestable P/S trade by David Kirn, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d18+72.22%-3.23%+0.53%-3.76%-5.91%
14d18+72.22%+0.60%+1.13%-0.54%-4.51%
30d18+61.11%+3.15%+2.14%+1.00%-7.34%
60d18+44.44%+9.32%+5.17%+4.15%+1.88%
90d18+66.67%+3.16%+5.51%-2.35%-12.29%
180d18+61.11%-11.10%+13.61%-24.71%-21.16%
1y18+83.33%-38.29%+24.68%-62.97%-70.74%
2y18(1 pending)+100.00%-66.63%+52.10%-118.73%-131.49%
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
FDMT · 942,485 shares · as of Jun 22, 2026
0492,142984,2841,476,4251,968,56720222023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 10 buys / 24 sellsCOVERAGE · 22 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
FDMT
4D MOLECULAR THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
114,746$10.47$1.20M942,485Jun 22, 2026Jun 23, 2026View →
FDMT
4D MOLECULAR THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
1,922$10.02$19.3K1,057,231Jun 1, 2026Jun 2, 2026View →
FDMT
4D MOLECULAR THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
750,000750,000Mar 25, 2026Mar 27, 2026View →
FDMT
4D MOLECULAR THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
267,500267,500Mar 6, 2025Mar 10, 2025View →
FDMT
4D MOLECULAR THERAPEUTICS, INC.
SALE
Chief Executive Officer
1,270148,730Jul 10, 2024Jul 12, 2024View →
FDMT
4D MOLECULAR THERAPEUTICS, INC.
SALE
Chief Executive Officer
11,653565,417Jul 10, 2024Jul 12, 2024View →
FDMT
4D MOLECULAR THERAPEUTICS, INC.
PURCHASE
Chief Executive Officer
11,653$14.42$168.0K1,070,806Jul 10, 2024Jul 12, 2024View →
FDMT
4D MOLECULAR THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
12,923$22.49$290.6K1,059,153Jul 10, 2024Jul 12, 2024View →
FDMT
4D MOLECULAR THERAPEUTICS, INC.
PURCHASE
Chief Executive Officer
1,270$15.78$20.0K1,072,076Jul 10, 2024Jul 12, 2024View →
FDMT
4D MOLECULAR THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
12,930$23.10$298.7K1,059,153Jun 24, 2024Jun 26, 2024View →
FDMT
4D MOLECULAR THERAPEUTICS, INC.
PURCHASE
Chief Executive Officer
12,930$14.42$186.5K1,072,083Jun 24, 2024Jun 26, 2024View →
FDMT
4D MOLECULAR THERAPEUTICS, INC.
SALE
Chief Executive Officer
12,930577,070Jun 24, 2024Jun 26, 2024View →
FDMT
4D MOLECULAR THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
92,001$27.13$2.50M1,059,153Feb 8, 2024Feb 12, 2024View →
FDMT
4D MOLECULAR THERAPEUTICS, INC.
SALE
Chief Executive Officer
5,696$18.41$104.9K1,151,154Jan 23, 2024Jan 25, 2024View →
FDMT
4D MOLECULAR THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
28,104$19.56$549.8K1,156,983Jan 5, 2024Jan 8, 2024View →
FDMT
4D MOLECULAR THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
133$20.11$2.7K1,156,850Jan 5, 2024Jan 8, 2024View →
FDMT
4D MOLECULAR THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
40,732$20.31$827.2K1,185,087Jan 4, 2024Jan 8, 2024View →
FDMT
4D MOLECULAR THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
4,702$18.13$85.2K1,225,819Dec 18, 2023Jan 8, 2024View →
FDMT
4D MOLECULAR THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
28,632$17.27$494.4K1,230,521Dec 15, 2023Jan 8, 2024View →
FDMT
4D MOLECULAR THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
590,000590,000Dec 11, 2023Dec 13, 2023View →
FDMT
4D MOLECULAR THERAPEUTICS, INC.
SALEGRANT
Gift
600,0001,259,153May 2, 2023May 4, 2023View →
FDMT
4D MOLECULAR THERAPEUTICS, INC.
PURCHASEGRANT
Gift
600,000600,000May 2, 2023May 4, 2023View →
FDMT
4D MOLECULAR THERAPEUTICS, INC.
SALE
Chief Executive Officer
16,449$20.22$332.7K1,859,153Feb 22, 2023Feb 23, 2023View →
FDMT
4D MOLECULAR THERAPEUTICS, INC.
SALE
Chief Executive Officer
17,090$20.93$357.7K1,876,509Feb 21, 2023Feb 23, 2023View →
FDMT
4D MOLECULAR THERAPEUTICS, INC.
SALE
Chief Executive Officer
907$21.49$19.5K1,875,602Feb 21, 2023Feb 23, 2023View →
FDMT
4D MOLECULAR THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
222,000222,000Feb 10, 2023Feb 14, 2023View →
FDMT
4D MOLECULAR THERAPEUTICS, INC.
SALE
Chief Executive Officer
8,625$20.19$174.1K1,893,599Jan 20, 2023Jan 23, 2023View →
FDMT
4D MOLECULAR THERAPEUTICS, INC.
SALE
Chief Executive Officer
10,899$20.03$218.3K1,902,224Jan 19, 2023Jan 23, 2023View →
FDMT
4D MOLECULAR THERAPEUTICS, INC.
SALE
Chief Executive Officer
26,349$23.39$616.2K1,913,123Dec 16, 2022Dec 19, 2022View →
FDMT
4D MOLECULAR THERAPEUTICS, INC.
SALE
Chief Executive Officer
27,595$22.66$625.4K1,939,472Dec 16, 2022Dec 19, 2022View →
FDMT
4D MOLECULAR THERAPEUTICS, INC.
SALE
Chief Executive Officer
31,433$23.56$740.6K1,968,567Dec 15, 2022Dec 19, 2022View →
FDMT
4D MOLECULAR THERAPEUTICS, INC.
SALE
Chief Executive Officer
1,500$24.13$36.2K1,967,067Dec 15, 2022Dec 19, 2022View →
FDMT
4D MOLECULAR THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
150,000150,000Feb 1, 2022Feb 3, 2022View →
FDMT
4D MOLECULAR THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
150,000150,000Mar 8, 2021Mar 10, 2021View →
Other insiders · FDMT
Loading peer insiders…
About this filer
CIK 0001834021
ROLE
Chief Executive Officer
PRIMARY
FDMT
COMPANIES
1
ACTIVE SINCE
Mar 2021
MARKETPEEL · /INSIDER/0001834021DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback